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Aim: To assess the relationship between both photoreceptor function and choroidal thickness and endothelin-1
(ET-1) plasma levels in patients with early stage retinitis pigmentosa (RP).
Main methods:We compared 24 RP patients (14 males and 10 females), 25 to 42 years of age (mean age: 34 ±
7 years) with 24 healthy controls (12 males and 12 females) aged between 28 and 45 years (mean 36 ±
6.8 years). All patients underwent visual ﬁeld test, electroretinogram and multifocal-electroretinogram and
choroidal thickness measurement by using spectral domain optical coherence tomography.
Key ﬁndings:RPpatients had a visual acuity of 0.95, amean defect of the visual ﬁeld of−7.90±1.75 dB, a pattern
standard deviation index of 6.09± 4.22 dB and a b-wave ERG amplitude of 45.08± 8.24 μV. Notably RP subjects
showed signiﬁcantly increased ET-1 plasma levels and reduced choroidal thickness compared with controls:
respectively, 2.143 ± 0.258 pg/ml vs. 1.219 ± 0.236 pg/ml; p b 0.002 and 226.75 ± 76.37 μm vs. 303.9 ±
39.87 μm; p b 0.03. Spearman's correlation test highlighted that the increase of ET-1 plasma levels was related
with the decrease of choroidal thickness (r=−0.702; p b 0.023) and the increase of implicit time in both ring
2 (r=−0.669; p b 0.034) and ring 3 (r=−0.883; p b 0.007) of mfERG.
Signiﬁcance: Increased ET-1 plasma levels may play a key role in the impairment of retinal and choroidal blood
ﬂow due to the vasoconstriction induced by ET-1. This could lead to worsening of the abiotrophic process of
the macular photoreceptors.lpighi, Opht
Bologna, Ita
icle under th© 2014 Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/ .0/).3Introduction
Endothelin-1 (ET-1), the most potent and long-acting vasoconstric-
tor of small and large vessels (Masaki et al., 1991)wasﬁrst isolated from
the culture supernatant of porcine aorta endothelium cells in 1988
(Yanagisawa et al., 1988). It ismainly synthesized and releasedby endo-
thelial cells of the arterial, venous and lymphatic vessels and is able to
modulate the secretion of renin, vasopressin and aldosterone which
play an important role in the regulation of vascular tone (Simonson
andDunn, 1990). ET-1 binding sites have been identiﬁed inmany ocular
tissues, such as iris, ciliary processes and both choroidal vasculature and
retinal vasculature (MacCumber et al., 1991).
ET-1 system plays a key role in both normal and pathological pro-
cesses which may also involve the eye; indeed several studies have
found increased ET-1 plasma levels in some ocular diseases such as
glaucoma (Sigiyama et al., 1997), thanks to its ability to reduce bothhalmology Service,
ly. Tel./fax: +39
e CC BY-NC-ND license (ocular blood ﬂow and retinal blood ﬂow, leading to ischemic damage
to optic nerve head and retinal ganglion cells (Polak et al., 2003), and
retinitis pigmentosa (RP) (Cellini et al., 2002).
RP is an inherited, degenerative retinal disorder characterized by bone
spicule-shaped pigment deposits in the retina, attenuated retinal blood
vessels and a pale, waxy optic nerve head with degeneration, atrophy
and ﬁnally loss of photoreceptors and retinal pigment epithelium (RPE),
leading to progressive visual impairment (Li et al., 1995). Furthermore
visual ﬁeld contraction and abnormalities in the electroretinographic
recording are characteristic features of the disease (Heckenlively
et al., 1988). Recently, a reduced choroidal thickness in RP patients
has been demonstrated by using spectral-domain optical coherence
tomography (SD-OCT) (Dhoot et al., 2013), whereas hemodynamic
studies have shown the relationship between the increase of ET-1
plasma levels and the decrease of both retinal blood ﬂow and choroi-
dal blood ﬂow not only in the advanced RP stages but also in the early
stages (Cellini et al., 2010) even before the appearance of any
ophthalmoscopic signs.
The purpose of this study was to assess the choroidal thickness and
the photoreceptor dysfunction of early RP patients in order to search
for a possible correlation with ET-1 plasma levels.http://creativecommons.org/licenses/by-nc-nd/ .0/).3
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Patients
A total of 24 patients (14 males and 10 females), aged 25 and
42 years (mean 34 ± 7 years), who were affected by early stage RP
were enrolled and compared with 24 age- and sex-matched healthy
controls (12 males and 12 females), aged between 28 and 45 years
(mean 36 ± 7 years). The tenets of the Declaration of Helsinki were
followed and, after a full explanation of the aim of the study and of
the procedures, all the participants signed written informed consent.
This study was reviewed and approved by the Institutional Ethics
Committee of the S. Orsola-Malpighi Hospital.
Clinical examination
RP diagnosis is usually based on detection of abnormalities of the vi-
sual ﬁeld, attenuation of the electroretinogram, and a pale optic nerve
head with narrowed retinal blood vessels and accumulation of bone
spicule-shaped pigment deposits in the peripheral retina at the ophthal-
moscopy. We included young RP patients with preserved visual func-
tion and excluded those who had systemic diseases, were taking any
medications or who had advanced posterior subcapsular cataract and
macular cystoid edema.
The diagnostic criteria for the early stage of RP are those described
by Hamel (2006): night blindness, peripheral visual ﬁeld defects,
normal or subnormal visual acuity, color vision and life habits, modest
attenuation of retinal arterioles, normal or fainly pale optic disk, absent
or rare peripheral bone spicule-shaped pigment deposits and a decrease
in maximum ERG amplitude. All participants underwent a complete
ophthalmological evaluation, including visual acuity, Goldmann
applanation tonometry and slit lamp examination of anterior and
posterior segment. Visual ﬁeld test, standard ERG (ERG), multifocal ERG
(mfERG) and choroidal thickness measurement were also performed.
Visual ﬁeld test
Visual ﬁeld test was performed by using standard automated
perimetry (SAP) with the Humphrey 740 ﬁeld analyzer 30.2 full
threshold program (Humphrey Instruments Inc., San Leandro, CA,
U.S.A.). Calculation ofmean defect (MD) and pattern standard deviation
(PSD) for each 30.2 visual ﬁeld were obtained using Humphrey
STATPAC software.
Electroretinogram stimulus and recording
Electroretinogram was recorded using Retimax Plus (CSO, Florence,
Italy). After pupil dilation with 1% tropicamide and topical anesthesia of
the cornea with 0.4% oxybuprocaine hydrochloride, HK-Loop ERG
electrodes, a ground electrode and the reference electrodes were
applied, respectively to the ocular surface, to the forehead and to the
temporal region. Electrical impedance was smaller than 5 kω for all
electrodes. ERGs were recorded from both eyes simultaneously, accord-
ing to International Society for Clinical Electrophysiology of Vision
(ISCEV) standards (Marmor et al., 2009), by using a standard ﬂash
strength of 2.5 cd·s·m−2. Band-pass ﬁlter was between 0.3 Hz and
300 Hz with an ampliﬁcation of 5 kwhile artifactual signals were auto-
matically removed. The amplitude of b-wave was measured from the
baseline and was expressed in microvolts (μV).
MfERG stimulus and recording
Multifocal electroretinogram was performed using Retimax Plus
(CSO, Florence, Italy). The arrangement of the electrodes was the same
we used to perform ERG. MfERG was recorded monocularly using a
61-hexagon stimulus according to the ISCEV guidelines (Hood et al.,2012), with a 21-inch video stimulating display (CRT monitor, 75-Hz
frame rate, cutoffs: 10–100Hz) subtending30° on either side ofﬁxation.
The room light was on during stimulation and the screen–patient dis-
tance was 28 cm. The radius of the central hexagon was 2° and a red
central-ﬁxation cross 2 mm in diameter was used. During stimulation,
each elementwas either black orwhite (93% contrast) and themean lu-
minance was 51.8 cd·m−2. Themean responses, assessed by the analy-
sis of ﬁve concentric stimulus rings, were passed through a band-pass
ﬁlter at between 10 Hz and 300 Hz.
The amplitude of P1 wave of each ring was expressed in microvolts
(μV) and the implicit time in milliseconds (ms) (Fig. 1).
SD-OCT image acquisition and analysis
SD-OCT is a noninvasive, widespread technique that allows in vivo
cross-sectional high resolution visualization of retinal structures and
choroid with a fast scanning speed (Ruggeri et al., 2007). However, to
enhance the quality of the images and to providemany details of the ar-
chitecture of the choroid, a new technique called enhanced depth imag-
ing (EDI) has been developed in the recent years and described
elsewhere (Spaide et al., 2008).We selected the horizontal scan running
directly through the center of the fovea of both eyes of each patient by
using spectral-domain optical coherence tomography (Heidelberg Engi-
neering GmbH, Heidelberg, Germany) with the EDI technique. Choroi-
dal thickness was measured manually and was deﬁned as the vertical
distance from the hyperreﬂective line of the retinal pigment epitheli-
um–Bruch's membrane complex to the innermost hyperreﬂective line
of the choroidal scleral interface, exactly below the foveola. The values
were expressed in micrometers (μm) (Fig. 1).
Endothelin-1 determination
For ET-1 measurements the plasma samples were drawn from the
antecubital vein and collected in a container with EDTA, cooled and
stored in ice. Subsequently, the samples were centrifuged at 4 °C and
frozen at −25 °C. After centrifugation the extraction was performed
using a Sep-column containing C-18 (Peninsula Laboratories, Belmont,
CA, USA) and ET-1 concentration was determined by using a commer-
cial radioimmunoassay (RIA) kit (Peninsula Laboratories, Belmont, CA,
USA), after that samples and standards were ﬁrstly incubated with
rabbit anti-ET-1 serum for 24 h at 4 °C. A second 24 h incubation was
performed after the addition of an iodinated tracer [125I]-ET-1. Free
and bound radioligands were separated with centrifugation and
radioactivity in the precipitate was counted with an automatic
gamma-counter. ET-1 concentration was expressed in picogram/
milliliter (pg/ml).
Statistical analysis
All datawere expressed as themean± standard deviation (SD). The
statistical analysis was performed with MedCalc 10.9.1 statistical pro-
gram(MedCalc Software, Ostend, Belgium), to assess the differences be-
tween RP patients and controls by using the Wilcoxon rank-sum test.
Spearman's correlation test was used to evaluate the relationship be-
tween abnormalities in both P1 amplitude and implicit time and choroi-
dal thickness and the association between ET-1 plasma levels and both
choroidal thickness andmfERG parameters. p values less than 0.05were
regarded as being statistically signiﬁcant.
Results
Best corrected visual acuity and intraocular pressure did not differ
signiﬁcantly between RP patients and controls, whereas there was a
signiﬁcant difference with regard to MD (p b 0.006), PSD (p b 0.001)
and both b-wave amplitude and a-wave ERG amplitude (p b 0.002 and
p b 0.019, respectively). Furthermore RP patients showed signiﬁcantly
Fig. 1. Representative enhanced depth imaging optical coherence tomography scans of 2 eyes and the corresponding multifocal ERG images: (A–B) patient with retinitis pigmentosa and
(C–D) control subject. There is a marked choroidal thickness difference between the 2 patients (108 vs. 288 μm, respectively). Choroidal thickness wasmeasured as the distance between
the hyperreﬂective lines of the retinal pigment epithelium–Bruch's membrane complex to the innermost hyperreﬂective line of the choroid–sclera junction. MfERG show attenuated
paracentral responses in retinitis pigmentosa compared with a healthy subject.
Table 2
Multifocal ERG characteristics in patients with retinitis pigmentosa and in healthy con-
trols.
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with healthy subjects: respectively, 2.143 ± 0.258 pg/ml vs. 1.219 ±
0.236 pg/ml (p b 0.002) and 226.75 ± 76.37 μm vs. 303.9 ± 39.87 μm
(p b 0.03) (Table 1).
No signiﬁcant correlation between standard ERG and plasmatic ET-1
levels (r =−0.511; p b 0.131) was observed.
Finally data obtained by mfERG demonstrated that RP subjects
had a statistically signiﬁcant decrease of P1 amplitude in rings 2, 3,
4 and 5 compared with controls, respectively (p b 0.01), (p b 0.027),
(p b 0.002) and (p b 0.007) and an increase of P1 implicit time in both
ring 2 (p b 0.018) and ring 3 (p b 0.001) (Table 2).
Spearman's correlation test highlighted that the increase of
ET-1 plasma levels was related with the decrease of choroidal
thickness (r =−0.702; p b 0.023; Fig. 2) and the increase of implicit
time in both ring 2 (r =−0.669; p b 0.034) and ring 3 (r =−0.883;
p b 0.007) of mfERG. Notably we also found a positive correlation
between the decreased choroidal thickness and the reduction of
P1 amplitude in both ring 2 (r = 0.787; p b 0.037) and ring 3 (r =
0.810; p b 0.001), whereas, as regards rings 1, 4 and 5, no statistically
signiﬁcant correlation was reported (Table 3).Table 1
Demographic and ocular parameters and ET-1 plasma levels in patients with retinitis
pigmentosa and in healthy controls.
Controls Retinitis pigmentosa p b 0.05
Age, years 36.0 ± 6.8 33.8 ± 7.3 0.155
Visual Acuity, decimals 0.97 ± 0.04 0.95 ± 0.07 0.235
SAP-PSD, dB 1.98 ± 0.98 6.09 ± 4.22 0.001
SAP-MD, dB −1.95 ± 0.83 −7.90 ± 1.75 0.006
ERG b-wave, μV 65.36 ± 9.84 45.08 ± 8.24 0.002
ERG a-wave, μV 38.16 + 5.57 28.13 + 5.77 0.019
ET-1, pg/ml 1.219 ± 0.236 2.143 ± 0.258 0.002
Choroidal thickness, μm 303.9 ± 39.87 226.75 ± 76.37 0.023
Note: Values are presented as means ± SD; n = 24 per group.Discussion
RP includes a group of hereditary disorders with variable clinical
presentation and wide range of severity, age of onset and progression
and is characterized by progressive visual impairment, visual ﬁeld loss
and abnormal ERG responses because diffusely involves photoreceptors
and RPE function.
Our results show that early stage RP patients with preserved central
visual acuity have decreased P1 amplitude, increase in P1 implicit time,
thinner subfoveal choroidal thickness and higher ET-1 plasmatic levels
compared with healthy subjects.
Both Cellini et al. (2002) and Vingolo et al. (2010) demonstrated
higher levels of ET-1 plasma concentration in RP subjects compared
with healthy patients, whereas Ohguro and associates found that
there were signiﬁcantly lower ET-1 plasmatic levels than those of con-
trols (Ohguro et al., 2010). Different disease heterogeneity, stages,Characteristic Controls Retinitis Pigmentosa p b 0.05
P1 amplitude, μV
Ring 1 0.94 ± 0.35 0.61 ± 0.79 0.432
Ring 2 0.67 ± 0.34 0.33 ± 0.23 0.010
Ring 3 0.56 ± 0.17 0.27 ± 0.23 0.027
Ring 4 0.53 ± 0.15 0.17 ± 0.22 0.002
Ring 5 0.50 ± 0.07 0.15 ± 0.19 0.007
P1 implicit time, ms
Ring 1 35.44 ± 5.92 38.47 ± 2.96 0.129
Ring 2 37.19 ± 1.31 41.04 ± 2.32 0.018
Ring 3 35.76 ± 0.82 40.29 ± 1.94 0.001
Ring 4 34.14 ± 3.85 34.48 ± 3.21 0.238
Ring 5 35.60 ± 1.51 36.07 ± 2.07 0.467
Note: Values are presented as means ± SD; n = 24 per group.
Fig. 2. Scatterplot showing the correlation between ET-1 plasmatic levels (picogram/mil-
liliter) and subfoveal choroidal thickness (micrometers) in patients with retinitis
pigmentosa (Spearman's correlation coefﬁcient, r =−0.702; p b 0.023).
389A. Finzi et al. / Life Sciences 118 (2014) 386–390race, sample size and the method used for the ET-1 determination may
justify contrasting results.
The thinnest choroidal thickness values we measured in early stage
RP patients compared with controls (p= 0.023), by using EDI SD-OCT,
are in agreement with those already demonstrated by Dhoot et al.
(2013) with the same objective technique.
Several previous hemodynamic studies showed a reduction in both
choroidal blood ﬂow and retinal blood ﬂow in RP, by using color Dopp-
ler imaging and laser Doppler ﬂowmetry (Langham and Kramer, 1990;
Akyol et al., 1995; Cellini et al., 1997; Schmidt et al., 2001; Falsini et al.,
2011; Grunwald et al., 1996) and in addition, other authors found a
positive correlation between increased ET-1 plasma concentration and
abnormalities in the microcirculation not only in the eye, but also in
the whole body (Cellini et al., 2010; Konieczka et al., 2012). Notably
we reported a negative association between choroidal thickness and
ET-1 (r = −0.702; p b 0.023) and hypothesize that the reduction of
choroidal thickness may be determined by the vasoconstrictor effect
of ET-1 which could cause choroidal vascular abnormalities and blood
ﬂow impairment with a resulting relative ischemia leading to worsen-
ing of the abiotrophic process of the macular photoreceptors.
The reason why ET-1 is increased in RP patients is not well under-
stood. Indeed ET-1 is mainly produced by vascular endothelial cells
but also different kind of cells may secrete ET-1 when they are under
stress conditions, such as hypoxia and oxidative stress. It has beenwide-
ly suggested that oxidative stress is a typical ﬁnding in RP and possibly
contributes to its pathogenesis (Martínez-Fernández de la Cámara et al.,
2013).
Furthermore some authors have hypothesized a primary vascular
dysregulation syndrome (Flammer et al., 2013) to explain all the signs
and symptoms both in the eye and in the body of RP patients. Finally
the term retinitis refers to an inﬂammatory component (Yoshida et al.,
2013a; Yoshida et al., 2013b) which could contribute to amicrovascularTable 3
Correlation between the amplitude of P1 in each of the ﬁve rings of mfERG and subfoveal
choroidal thickness.
P1 amplitude, μV Choroidal thickness, μm p b 0.05
Ring 1 r = 0.043 0.906
Ring 2 r = 0.787 0.037
Ring 3 r = 0.810 0.001
Ring 4 r = 0.492 0.149
Ring 5 r = 0.104 0.774dysfunction. Thus oxidative stress, vascular dysfunction and inﬂamma-
tion interact to enhance ET-1 production and secretion. Increased ET-1
plasmatic levels may lead to unstable ocular blood supply, by altering
the regulation of retinal and choroidal blood ﬂow and this, in turn,
leads to an increase in free radicals and chronic oxidative stress which
may stimulate cells to secrete more ET-1. From an accurate analysis of
the data reported in literature and from our study results we suppose
that the increase of ET-1 plasmatic levels in RP patients may be a conse-
quence of the pathogenetic elements of the disease but also a potential
modifying factor able to modulate the manifestation and/or the pro-
gression of the disease itself.
Multifocal ERG, described for the ﬁrst time by Sutter and Tran
(1992), allows recording ERG waves in response to a series of stimuli
presented in different points of the visual ﬁeld and provides a simulta-
neous estimation of the functionality of each retinal area and thus alter-
ations of mfERG may constitute an early indication of local retinal
damage to the cone system. The recordings show the activity of the
outer retina, especially photoreceptors and bipolar cells. Indeed we
demonstrated that RP subjects, compared with healthy controls, show
abnormalities in P1 amplitudes in each ring, with the exception of
ring 1, and also that the reduction of P1 amplitude in both ring 2 and
ring 3 was positively related to the thinning of the choroid; respectively
(r= 0.787; p b 0.037) and (r= 0.810; p b 0.001). Furthermore, our pa-
tients had a signiﬁcant increased implicit time in both ring 2 and ring 3
compared with controls and this data was very well related to the
increase in ET-1 plasma levels. Indeed Kobayashi et al. (2005) demon-
strated that ET-1 increases the intracellular Ca2+ concentration in glial
and neuronal cells through ET-A receptors, thereby favoring the
glutamate-induced death of retinal neurons, especially amacrine cells,
which have neural connectionswith bipolar, horizontal and retinal gan-
glion cells and play a key role in themodulation of the activities of these
cells. For this reason the glutamate neurotoxicity is enhanced by the in-
crease of ET-1. The death of amacrine cells may lead to abnormal neural
transmission and explain the increase of implicit time in mfERG. These
functional changes are statistically more signiﬁcant in both ring 2 and
ring 3 because of the anatomical distribution of bipolar cells in the
macula, which are poor in the foveal region and becomemore dense to-
ward the parafovea and perifovea (Miyake, 1998).
From our results it is worth noting that mfERG ﬁndings may not be
simply explained by a primary photoreceptor degeneration but may
be inﬂuenced by plasmatic ET-1 levels. Indeedwe suppose amechanism
of photoreceptor ischemia due to reduced choroidal blood ﬂow, caused
by increased ET-1 plasmatic levels in RP eyes, leading to abnormal elec-
trophysiological responses.
This study has some limitations. First, the sample size was small be-
cause participants were accurately selected among young healthy RP
patients, to limit confounding factors, such as age and systemic diseases
which could affect plasmatic ET-1 levels. It is likely that results may be
more heterogeneous by considering a wider RP population. Second,
we did not evaluate intraocular ET-1 concentration; indeed ET-1 plasma
levels obtained in our study might not reﬂect the intraocular activity of
this peptide.Conclusions
Our study suggests that increased ET-1 plasma levels may play a key
role in the impairment of choroidal blood ﬂow and thickness and may
favor glutamate-induced toxicity to retinal cells leading to worsening
of the abiotrophic process of the macular photoreceptors and to abnor-
malities in neural connections.
Although our results require further conﬁrmation and investigation,
this studymight provide reasonable data about the possibility to use an-
tagonists of ET-1 with the purpose of improving the ocular blood ﬂow
and reducing the glutamate neurotoxicity to ameliorate the function
of the macular photoreceptors and enhance survival of cells.
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